现已公认,血小板在PTCA术中、术后缺血性并发症如急性血管闭塞中起着重要作用,Ⅱb/Ⅲa受体是血小板聚集的终末共同途径。因此本实验对PTCA术中有并发症倾向的高危病人观察了直接对抗血小板糖蛋白Ⅱb/Ⅲa受体的嵌合体单克隆抗体片段(c7E3 Fab)的疗效。 这是一项前瞻性随机双盲试验,56个中 It is now recognized that platelet plays an important role in postoperative PTCA and postoperative ischemic complications such as acute vascular occlusion. The IIb / IIIa receptor is the common pathway of terminal platelet aggregation. In this study, we evaluated the efficacy of the chimeric monoclonal antibody fragment (c7E3 Fab) that directly targets platelet glycoprotein IIb / IIIa receptor in high-risk patients with a tendency to complications during PTCA surgery. This is a prospective, randomized double-blind trial of 56